Equities

Cannara Biotech Inc

Cannara Biotech Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)0.72
  • Today's Change-0.01 / -1.37%
  • Shares traded3.02k
  • 1 Year change-26.53%
  • Beta1.1502
Data delayed at least 15 minutes, as of Jun 14 2024 18:28 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cannara Biotech Inc. is a Canada-based vertically integrated producer of premium-grade cannabis and cannabis-derivative products for the Quebec and Canadian markets. It operates through its wholly owned subsidiaries, Cannara Biotech (Quebec) Inc. and Cannara Biotech (Valleyfield) Inc. The Company owns two mega facilities based in Quebec spanning over 1,650,000 square feet, providing the Company with 100,000 kilograms of annualized cultivation output. It operates in two segments: Cannabis operations and Real estate operations. The Cannabis operations, which encompasses the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and other cannabis services (Cannabis operations). The Real estate operations, related to the Farnham and Valleyfield building (Real estate operations). The Company’s brand portfolio includes Tribal, Nugz, and Orchid CBD. Orchid CBD is a wellness brand that provides premium CBD-dominant cannabis.

  • Revenue in CAD (TTM)73.38m
  • Net income in CAD6.22m
  • Incorporated2017
  • Employees--
  • Location
    Cannara Biotech IncSuite 2050 - 1055, West Georgia StreetVANCOUVER V6E 3P3CanadaCAN
  • Phone+1 (514) 913-9136
  • Fax+1 (514) 913-9136
  • Websitehttps://www.cannara.ca/en/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
MustGrow Biologics Corp4.71m-665.06k47.18m0.00--10.42--10.01-0.0134-0.01340.09360.09120.7632--45.31---10.77-50.41-14.00-59.28-----14.11-298.73----0.1393--72,619.13372.5487.84------
Covalon Technologies Ltd26.24m-2.77m49.88m----2.48--1.90-0.1123-0.11231.060.80211.021.844.53---10.83-18.06-12.67-27.1055.8451.89-10.57-27.064.85--0.0597--46.56-0.09651.79--12.21--
KDA Group Inc186.28k133.66k49.99m--141.793.2257.22268.350.0020.09260.00120.08860.0079--0.0693---0.4146-17.96-0.8534-44.6936.5126.76-52.24-28.00---4.310.1287---22.20-62.03106.88--31.67--
LSL Pharma Group Inc12.17m-4.62m51.84m----3.22--4.26-0.056-0.0560.14660.14890.39292.594.87---14.92---21.69--19.76---37.97--0.4505-0.84650.4938--------------
Helix Biopharma Corp.0.00-5.65m58.83m9.00---------0.0277-0.02770.00-0.00120.00----0.00-318.95-261.49-574.76-------------2,825.00--------4.16---28.36--
Simply Better Brands Corp95.08m-30.01m59.65m--------0.6274-0.4156-0.43051.32-0.08542.7112.6817.69---85.10-63.90-361.23-215.4853.52---31.40-29.460.2536-19.653.20--22.08---96.41------
Satellos Bioscience Inc0.00-21.13m60.91m12.00--1.77-----0.1718-0.17180.000.30590.00----0.00-93.29-107.22-109.86-136.58------------0.00-------40.33--459.46--
Medmira Inc407.78k-2.92m64.65m65.00------158.54-0.0042-0.00420.0006-0.02290.09960.78990.3142---71.41-69.95----61.5466.76-717.02-187.610.1342-2.09-----54.57-5.98-46.08------
Cannara Biotech Inc73.38m6.22m64.81m--10.360.81695.450.88320.06950.06950.81730.88140.53372.087.46--4.52-4.466.23-4.9510.0617.868.48-15.880.3582-2.460.384--59.91--201.26------
ZYUS Life Sciences Corp387.00k-41.25m73.68m2.00--3.67--190.39-0.5751-0.57510.00570.28330.0165--0.7911---175.44-57.88-242.41-71.1946.25-16.16-10,658.40-10,367.370.315-7.990.3295--17.79213.99-72.73------
Theratechnologies Inc107.27m-24.72m80.93m89.00------0.7544-0.8509-0.85093.29-0.73491.031.897.81---23.78-26.32-128.23-55.4374.1065.90-23.04-38.261.03-0.9191.71--2.1312.5849.28---37.83--
Data as of Jun 14 2024. Currency figures normalised to Cannara Biotech Inc's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.